Tréidlia Biovet

What Tréidlia Biovet does

Tréidlia Biovet Pty Ltd is an independent, Australian-owned animal health company founded in 2012 and headquartered at an accredited facility in Seven Hills, Sydney. The company specialises in the development and manufacture of specialty veterinary vaccines across bacterial, recombinant, and viral modalities, targeting production animals (pigs, cattle, poultry, fish), companion and performance animals, zoos, and wildlife collections. Notable products include a portfolio of bacterial bacterins (including autogenous vaccines derived from farm-specific isolates), recombinant vaccines such as the TBV Custom Footroot R-Pilus Vaccine co-developed with the University of Sydney against ovine footrot, the TBV Rotavax vaccine for Australian Pigeon Rotavirus, and the TBV Nodavax vaccine for marine Nodavirus in fish, plus a niche conservation range for endangered Australian species.

The company operates a B2B, quote-based sales model targeting veterinarians, farm managers, research institutions, zoos, and other animal health companies, with autogenous vaccines gated by veterinary prescription. Beyond products, Tréidlia Biovet runs three service lines: diagnostic services (pathogen isolation, PCR, subtyping, ELISA antibody titre monitoring, Salmonella monitoring), contract manufacturing (sterile filling, QC testing, intermediate manufacture up to release for sale), and collaborative R&D under short- and long-term partnerships. Marketing is primarily relationship-driven via the company website, industry event participation (e.g., Australasian Veterinary Poultry Association, APV Conference), and direct enquiry-led confidential consultations.

Commercial scale is modest: the firm employs between 11 and 50 people, serves primarily Australian customers with selective overseas reach, and discloses no external funding rounds, revenue, or institutional ownership. Strategic positioning emphasises bespoke, niche solutions over mass-market commodity vaccines, with selective One Health extensions into human health evidenced by an August 2020 collaboration with NSW Health for COVID-19 testing components and a 2021 collaboration with Snoretox Pty Ltd on a muscle atony product. The company remains privately held and founder-led, with growth financed through retained earnings rather than disclosed external capital.

Name

Tréidlia Biovet

Legal name

Tréidlia Biovet Pty Ltd

Website

https://treidlia.com.au

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Tréidlia Biovet is an Australian animal health company founded in 2012 that develops and manufactures specialty veterinary vaccines (bacterial, recombinant, viral) and provides diagnostic, contract manufacturing, and R&D services to veterinarians, livestock producers, zoos, and research institutions.

Ownership category

akta.pro rank

Product category

Veterinary Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071)

akta.pro primary industry

Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO) (HLAMAKAI)

akta.pro secondary industries

Veterinary Vaccines (Biologics) (HLAMAEAL), Autogenous (Herd-Specific) Vaccines (HLAMAKAF), Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB), Wildlife & Zoo/Exotic Animal Vaccines (HLAMAKAG), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM)

Keywords

• Veterinary vaccines
• Animal biotechnology
• Autogenous vaccines
• Veterinary diagnostics
• Contract manufacturing

Headquarters

HQ city

Seven Hills

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Vaccine Products: Sale of specialty veterinary vaccines including bacterial, recombinant, and viral vaccines for pigs, cattle, poultry, fish, and other animals. Includes autogenous (farm-specific) vaccines and conservation products for wildlife.
2. Diagnostic Services: Laboratory diagnostic services including pathogen isolation, PCR identification tests, subtyping of isolates, ELISA monitoring of antibody titres, and Salmonella monitoring.
3. Contract Manufacturing: Customised contract manufacturing services for other organisations including product manufacture up to release for sale, intermediate product manufacture, sterile filling and QC testing.
4. Research & Development Services: R&D services conducted internally and in collaboration with scientific and research partners under long-term or short-term collaborative partnerships.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Tréidlia Biovet develops and manufactures specialty veterinary vaccines — including bacterial, recombinant, and viral products — for pigs, cattle, poultry, fish, and endangered wildlife. Core offerings include autogenous (farm-specific) vaccines, recombinant vaccines such as TBV Custom Footroot R-Pilus, TBV Rotavax, and TBV Nodavax, plus viral and conservation vaccines. The company also provides diagnostic laboratory services, custom contract manufacturing, and collaborative research and development for veterinarians, agribusiness, zoos, and research institutions.

Product overview

Tréidlia Biovet is a specialty veterinary biotechnology company offering a portfolio of vaccine products and laboratory services. The core product line includes Bacterial Vaccines (autogenous and conventional), Recombinant Vaccines (TBV Custom Footroot R-Pilus Vaccine, TBV Rotavax Vaccine for Pigeons, TBV Nodavax Vaccine), Viral Vaccines, and Conservation Products for wildlife and endangered species. These products are complemented by three service offerings: Diagnostic Services (PCR, ELISA, pathogen isolation, Salmonella monitoring), Contract Manufacturing (sterile filling, QC testing, product release), and Research & Development (internal and collaborative). The company operates from facilities in Seven Hills, Sydney, and was founded in 2012.

Differentiator

Problem solved

Functional benefit

Products and services

• Bacterial Vaccines Specialty bacterial vaccines targeting common endemic pathogens in pigs, cattle, poultry, fish and other animals; some variants are produced autogenously using farm-isolated strains for veterinarians and livestock producers facing strain variation not covered by off-the-shelf vaccines.
• Recombinant Vaccines Recombinant subunit vaccines for specific diseases in sheep (footrot), pigeons (rotavirus), and fish (marine Nodavirus); the footrot vaccine is customised to each farm based on serogroup test results. Intended for veterinarians and producers managing difficult-to-control or species-specific viral and bacterial indications.
• Viral Vaccines Specialty viral vaccines manufactured in specific circumstances for various animal species, available where standard commercial options do not exist. Produced by Tréidlia Biovet for veterinary use under custom arrangements.
• Conservation Products Vaccines and innovative biological products for zoos, wildlife collections, and conservation programs targeting preservation of rare and endangered Australian wildlife species such as the Bilby, Dunnart, and Orange Bellied Parrot.
• Diagnostic Services Laboratory diagnostic services including isolation of pathogens, identification tests such as PCR, subtyping of isolates, ELISA monitoring of antibody titres, and Salmonella monitoring, provided to veterinarians, producers, and research institutions.
• Contract Manufacturing Customised contract manufacturing services for other organisations covering product manufacture up to release for sale, intermediate product manufacture, sterile filling, and QC testing of veterinary biologics.
• Research & Development Services Research and development services delivered internally and in collaboration with scientific and research partners under long- or short-term collaborative partnerships, developing specialty and bespoke veterinary biologics.

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered minor and core.

• Snoretox Pty LtdminorStrategic or Co-development Partner · 1 May 2021Collaborative partner Snoretox Pty Ltd won a prestigious grant to develop their innovative muscle atony product for veterinary and human health applications. Tréidlia Biovet supported this collaborative development effort, exemplifying the One Health concept.
• NSW HealthminorStrategic or Co-development Partner · 1 August 2020Tréidlia Biovet formed collaboration with NSW Health in August 2020 to bulk manufacture requirements for COVID-19 testing. This represented the company's first foray into human health applications, demonstrating capability expansion under the One Health concept.
• University of SydneycoreStrategic or Co-development PartnerJoint development of TBV Custom Footroot R-Pilus Vaccine, a recombinant vaccine against Dichelobacter nodosus (causative agent of ovine footrot). The subunit vaccine is customised to suit each farm based on serogroup test results, demonstrating collaborative R&D capability.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Zoetis: Global leader in animal health pharmaceuticals and vaccines with extensive livestock and companion animal portfolio. Competes with Tréidlia in autogenous and specialty vaccines, but at vastly greater scale and geographic reach.
• Boehringer Ingelheim Animal Health: Major animal health player with deep vaccine franchise across livestock species. Overlaps with Tréidlia in livestock and aquaculture vaccines, but serves global markets and offers mass-market catalog products.
• MSD Animal Health (Merck Animal Health): Global animal health division with a broad vaccine and pharmaceutical portfolio spanning livestock, poultry, and aquaculture. A potential competitor and partner for Tréidlia's specialty and recombinant vaccine pipeline.
• Ceva Santé Animale: Large privately-held animal health company strong in livestock and poultry vaccines. Overlaps with Tréidlia in bacterial and recombinant vaccines for production animals.
• Hipra: Spanish animal health company specializing in veterinary biologicals and vaccines for livestock and aquaculture. Comparable in specialty vaccine focus and recombinant technology development.
• Virbac: Global animal health company with a meaningful specialty vaccines portfolio. Comparable in offering customized and niche veterinary biological solutions across species.
• Dechra Pharmaceuticals (Elanco): Specialty animal health company (now part of Elanco) with focus on niche veterinary pharmaceuticals and biologicals. Comparable specialty/niche positioning though historically more companion-animal focused.

Direct peers

• Phibro Animal Health: Animal health company with a notable autogenous vaccine business alongside nutritional specialties. Closest direct peer to Tréidlia's autogenous/herd-specific vaccine model, though significantly larger and US-focused.
• Vaxxinova: Animal health company focused on autogenous and custom vaccines for livestock and poultry. Direct peer to Tréidlia's core autogenous vaccine business with similar business model and customer profile.

Regional players

• Apiam Animal Health: Australian veterinary services and animal health company. Regional peer with overlapping customer base (Australian livestock producers and veterinarians) and potential partnership route for Tréidlia's distribution.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tréidlia Biovet